CXCL5
Citokinski ligand 5 (C-X-C motiv) jest protein koji je kod ljudi kodiran genom CXCL5 ili ENA78 sa hromosoma 4.[5][6]
Aminokiselinska sekvenca
[uredi | uredi izvor]Dužina polipeptidnog lanca je 114 aminokiselina, а molekulska težina 11.972 Da.[7]
10 | 20 | 30 | 40 | 50 | ||||
---|---|---|---|---|---|---|---|---|
MSLLSSRAAR | VPGPSSSLCA | LLVLLLLLTQ | PGPIASAGPA | AAVLRELRCV | ||||
CLQTTQGVHP | KMISNLQVFA | IGPQCSKVEV | VASLKNGKEI | CLDPEAPFLK | ||||
KVIQKILDGG | NKEN |
Funkcija
[uredi | uredi izvor]Protein kodiran ovim genom, CXCL5 je mali citokin u porodici CXC hemokina koji je također poznat kao peptid 78 (ENA-78) za aktiviranje neutrofila izvedenih iz epitela. Proizvodi se nakon stimulacije ćelija upalnim citokinima interleukinom-1 ili faktorom nekroze tumora-alfa.[8] Ekspresija CXCL5 je također uočena kod eozinofila i može se inhibirati interferonskim tipom II IFN-γ.[9] Ovaj hemokin stimulira hemotaksiju neutrofila koji imaju angiogena svojstva. Izaziva ove efekte interakcijom sa ćelijskom površinom hemokinskih receptora CXCR1 i CXCR2.[9] Gen za CXCL5 kodira četiri egzona, a na hromosomu 4 nalazi se sa neloliko drugih hemokinskih gena.[8][10] CXCL5 je uključen u remodeliranje vezivnog tkiva.[9] Također je opisan kao regulator homeostaze neutrofila.[11]
Klinički značaj
[uredi | uredi izvor]CXCL5 igra ulogu u smanjenju osjetljivosti na bol od opekotina kod nekih osoba i predstavlja "potencijalni cilj koji se može koristiti za razumijevanje više o boli kod drugih upalnih stanja kao što su artritis i cistitis.[12] Poznato je da CXCL5 ima hemotaksijske i aktivirajuće funkcije na neutrofile, uglavnom tokom akutnih upalnih odgovora. Međutim, ekspresija CXCL5 je također veća u aterosklerozi (hronično upalno stanje), ali nije povezana s infiltracijom neutrofila. Umjesto toga, CXCL5 ima zaštitnu ulogu u aterosklerozi ,direktno kontrolirajući stvaranje makrofaga pjenaste ćelije.[13]
Reference
[uredi | uredi izvor]- ^ a b c GRCh38: Ensembl release 89: ENSG00000163735 - Ensembl, maj 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000029371 - Ensembl, maj 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Chang MS, McNinch J, Basu R, Simonet S (Nov 1994). "Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene". J Biol Chem. 269 (41): 25277–82. doi:10.1016/S0021-9258(18)47243-2. PMID 7929219.
- ^ "Entrez Gene: CXCL5 chemokine (C-X-C motif) ligand 5".
- ^ "UniProt, P42830" (jezik: engleski). Pristupljeno 23. 10. 2021.
- ^ a b Chang MS, McNinch J, Basu R, Simonet S (1994). "Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene". J. Biol. Chem. 269 (41): 25277–82. doi:10.1016/S0021-9258(18)47243-2. PMID 7929219.
- ^ a b c Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, Egesten A (2003). "Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils". Clin. Exp. Allergy. 33 (4): 531–7. doi:10.1046/j.1365-2222.2003.01609.x. PMID 12680872. S2CID 2449190.
- ^ O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4". Cytogenet. Cell Genet. 84 (1–2): 39–42. doi:10.1159/000015209. PMID 10343098. S2CID 8087808.
- ^ Mei J, Liu Y, Dai N, Hoffmann C, Hudock KM, Zhang P, Guttentag SH, Kolls JK, Oliver PM, Bushman FD, Worthen GS (2012). "Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice". Journal of Clinical Investigation. 122 (3): 974–986. doi:10.1172/JCI60588. PMC 3287232. PMID 22326959.
- ^ Dawes JM, Calvo M, Perkins JR, Paterson KJ, Kiesewetter H, Hobbs C, Kaan TK, Orengo C, Bennett DL, McMahon SB (juli 2011). "CXCL5 Mediates UVB Irradiation-Induced Pain". Sci Transl Med. 3 (90): 90ra60. doi:10.1126/scitranslmed.3002193. PMC 3232447. PMID 21734176. Sažetak – FierceBiotech.
- ^ Rousselle A, Qadri F, Leukel L, Yilmaz R, Fontaine JF, Sihn G, Bader M, Ahluwalia A, Duchene J (2013). "CXCL5 limits macrophage foam cell formation in atherosclerosis". Journal of Clinical Investigation. 123 (3): 1343–7. doi:10.1172/JCI66580. PMC 3582141. PMID 23376791.
Dopunska literatura
[uredi | uredi izvor]- Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A (2007). "A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5". J. Immunol. 179 (7): 4849–56. doi:10.4049/jimmunol.179.7.4849. PMC 3696729. PMID 17878384.
- Walz A, Schmutz P, Mueller C, Schnyder-Candrian S (1997). "Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease". J. Leukoc. Biol. 62 (5): 604–11. doi:10.1002/jlb.62.5.604. PMID 9365115. S2CID 20141618.
- Struyf S, Proost P, Van Damme J (2004). "Regulation of the immune response by the interaction of chemokines and proteases". Adv. Immunol. Advances in Immunology. 81: 1–44. doi:10.1016/S0065-2776(03)81001-5. ISBN 978-0-12-022481-4. PMID 14711052.
- Walz A, Burgener R, Car B, et al. (1992). "Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8". J. Exp. Med. 174 (6): 1355–62. doi:10.1084/jem.174.6.1355. PMC 2119025. PMID 1744577.
- Power CA, Furness RB, Brawand C, Wells TN (1995). "Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets". Gene. 151 (1–2): 333–4. doi:10.1016/0378-1119(94)90682-3. PMID 7828901.
- Corbett MS, Schmitt I, Riess O, Walz A (1995). "Characterization of the gene for human neutrophil-activating peptide 78 (ENA-78)". Biochem. Biophys. Res. Commun. 205 (1): 612–7. doi:10.1006/bbrc.1994.2709. PMID 7999089.
- Koch AE, Kunkel SL, Harlow LA, et al. (1994). "Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis". J. Clin. Invest. 94 (3): 1012–8. doi:10.1172/JCI117414. PMC 295150. PMID 8083342.
- Power CA, Clemetson JM, Clemetson KJ, Wells TN (1996). "Chemokine and chemokine receptor mRNA expression in human platelets". Cytokine. 7 (6): 479–82. doi:10.1006/cyto.1995.0065. PMID 8580362.
- Ahuja SK, Murphy PM (1996). "The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor". J. Biol. Chem. 271 (34): 20545–50. doi:10.1074/jbc.271.34.20545. PMID 8702798.
- Keates S, Keates AC, Mizoguchi E, et al. (1997). "Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis". Am. J. Physiol. 273 (1 Pt 1): G75–82. doi:10.1152/ajpgi.1997.273.1.G75. PMID 9252512.
- Wuyts A, Proost P, Lenaerts JP, et al. (1998). "Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78". Eur. J. Biochem. 255 (1): 67–73. doi:10.1046/j.1432-1327.1998.2550067.x. PMID 9692902.
- Wyrick PB, Knight ST, Paul TR, et al. (1999). "Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis". J. Infect. Dis. 179 (4): 954–66. doi:10.1086/314676. PMID 10068592.
- Wuyts A, Govaerts C, Struyf S, et al. (1999). "Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms". Eur. J. Biochem. 260 (2): 421–9. doi:10.1046/j.1432-1327.1999.00166.x. PMID 10095777.
- Hogaboam CM, Bone-Larson CL, Steinhauser ML, et al. (1999). "Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines". FASEB J. 13 (12): 1565–74. doi:10.1096/fasebj.13.12.1565. hdl:2027.42/154508. PMID 10463948. S2CID 7043800.
- Luu NT, Rainger GE, Nash GB (2000). "Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils". J. Immunol. 164 (11): 5961–9. doi:10.4049/jimmunol.164.11.5961. PMID 10820279.
- Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV (2000). "Control of chemokine production at the blood–retina barrier". Immunology. 101 (3): 426–33. doi:10.1046/j.0019-2805.2000.01105.x. PMC 2327097. PMID 11106948.
- Zhang C, Thornton MA, Kowalska MA, et al. (2001). "Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus". Blood. 98 (3): 610–7. doi:10.1182/blood.V98.3.610. PMID 11468158.
- Chandrasekar B, Melby PC, Sarau HM, et al. (2003). "Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway". J. Biol. Chem. 278 (7): 4675–86. doi:10.1074/jbc.M207006200. PMID 12468547.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
Vanjski linkovi
[uredi | uredi izvor]- Lokacija ljudskog genoma CXCL5 i stranica sa detaljima o genu CXCL5 u UCSC Genome Browseru.